Literature DB >> 17168727

Arginine mimetic structures in biologically active antagonists and inhibitors.

Lucija Peterlin Masic1.   

Abstract

Peptidomimetics have found wide application as bioavailable, biostable, and potent mimetics of naturally occurring biologically active peptides. L-Arginine is a guanidino group-containing basic amino acid, which is positively charged at neutral pH and is involved in many important physiological and pathophysiological processes. Many enzymes display a preference for the arginine residue that is found in many natural substrates and in synthetic inhibitors of many trypsin-like serine proteases, e.g. thrombin, factor Xa, factor VIIa, trypsin, and in integrin receptor antagonists, used to treat many blood-coagulation disorders. Nitric oxide (NO), which is produced by oxidation of L-arginine in an NADPH- and O(2)-dependent process catalyzed by isoforms of nitric oxide synthase (NOS), exhibits diverse roles in both normal and pathological physiologies and has been postulated to be a contributor to the etiology of various diseases. Development of NOS inhibitors as well as analogs and mimetics of the natural substrate L-arginine, is desirable for potential therapeutic use and for a better understanding of their conformation when bound in the arginine binding site. The guanidino residue of arginine in many substrates, inhibitors, and antagonists forms strong ionic interactions with the carboxylate of an aspartic acid moiety, which provides specificity for the basic amino acid residue in the active side. However, a highly basic guanidino moiety incorporated in enzyme inhibitors or receptor antagonists is often associated with low selectivity and poor bioavailability after peroral application. Thus, significant effort is focused on the design and preparation of arginine mimetics that can confer selective inhibition for specific trypsin-like serine proteases and NOS inhibitors as well as integrin receptor antagonists and possess reduced basicity for enhanced oral bioavailability. This review will describe the survey of arginine mimetics designed to mimic the function of the arginine moiety in numerous peptidomimetic compounds (thrombin inhibitors, factor Xa inhibitors, factor VIIa inhibitors, integrin receptor antagonists, nitric oxide synthase inhibitors), with the aim of obtaining better activity, selectivity and oral bioavailability.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17168727     DOI: 10.2174/092986706779026101

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  11 in total

1.  Selective monocationic inhibitors of neuronal nitric oxide synthase. Binding mode insights from molecular dynamics simulations.

Authors:  He Huang; Haitao Ji; Huiying Li; Qing Jing; Kristin Jansen Labby; Pavel Martásek; Linda J Roman; Thomas L Poulos; Richard B Silverman
Journal:  J Am Chem Soc       Date:  2012-07-10       Impact factor: 15.419

2.  Design and characterization of the first peptidomimetic molecule that prevents acidification-induced closure of cardiac gap junctions.

Authors:  Vandana Verma; Bjarne Due Larsen; Wanda Coombs; Xianming Lin; Eliana Sarrou; Steven M Taffet; Mario Delmar
Journal:  Heart Rhythm       Date:  2010-06-26       Impact factor: 6.343

3.  Modification and Functionalization of the Guanidine Group by Tailor-made Precursors.

Authors:  Tobias G Kapp; Maximilian Fottner; Horst Kessler
Journal:  J Vis Exp       Date:  2017-04-27       Impact factor: 1.355

4.  Structural basis for plasmepsin V inhibition that blocks export of malaria proteins to human erythrocytes.

Authors:  Anthony N Hodder; Brad E Sleebs; Peter E Czabotar; Michelle Gazdik; Yibin Xu; Matthew T O'Neill; Sash Lopaticki; Thomas Nebl; Tony Triglia; Brian J Smith; Kym Lowes; Justin A Boddey; Alan F Cowman
Journal:  Nat Struct Mol Biol       Date:  2015-07-27       Impact factor: 15.369

5.  Peptidomimetics of Arg-Phe-NH2 as small molecule agonists of Mas-related gene C (MrgC) receptors.

Authors:  Niyada Hin; Jesse Alt; Sarah C Zimmermann; Greg Delahanty; Dana V Ferraris; Camilo Rojas; Fengxian Li; Qin Liu; Xinzhong Dong; Barbara S Slusher; Takashi Tsukamoto
Journal:  Bioorg Med Chem       Date:  2014-09-19       Impact factor: 3.641

6.  Synthesis and Evaluation of Oxyguanidine Analogues of the Cysteine Protease Inhibitor WRR-483 against Cruzain.

Authors:  Brian D Jones; Anna Tochowicz; Yinyan Tang; Michael D Cameron; Laura-Isobel McCall; Ken Hirata; Jair L Siqueira-Neto; Sharon L Reed; James H McKerrow; William R Roush
Journal:  ACS Med Chem Lett       Date:  2015-12-15       Impact factor: 4.345

7.  First steps in the direction of synthetic, allosteric, direct inhibitors of thrombin and factor Xa.

Authors:  Jenson Verghese; Aiye Liang; Preet Pal Singh Sidhu; Michael Hindle; Qibing Zhou; Umesh R Desai
Journal:  Bioorg Med Chem Lett       Date:  2009-06-06       Impact factor: 2.823

Review 8.  Recent advances toward improving the bioavailability of neuronal nitric oxide synthase inhibitors.

Authors:  He Huang; Richard B Silverman
Journal:  Curr Top Med Chem       Date:  2013       Impact factor: 3.295

9.  Long-lasting effects of oxy- and sulfoanalogues of L-arginine on enzyme actions.

Authors:  Tatyana A Dzimbova; Peter B Milanov; Tamara I Pajpanova
Journal:  J Amino Acids       Date:  2013-10-24

10.  Simplified 2-aminoquinoline-based scaffold for potent and selective neuronal nitric oxide synthase inhibition.

Authors:  Maris A Cinelli; Huiying Li; Georges Chreifi; Pavel Martásek; Linda J Roman; Thomas L Poulos; Richard B Silverman
Journal:  J Med Chem       Date:  2014-02-10       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.